hostile takeover

Latest Headlines

Latest Headlines

Valeant offers a stick, a carrot and a May 12 deadline to Cephalon investors

The CEO of Canada's Valeant Pharmaceuticals has marshaled all of his arguments in favor of a hostile takeover of Cephalon ($CEPH) in a letter designed to woo shareholders, offering to bump the pharma

Valeant may sweeten Cephalon bid

Valeant says it just might be willing to up its bid for Cephalon--once it gets its hands on the books for its due diligence work. Cephalon has been fending off Valeant's hostile acquisition effort,

Cephalon shares rocket up after Valeant makes $5.7B hostile bid

Rebuffed after making a private overture, Canada's Valeant Pharmaceuticals ($VRX) has gone hostile in its pursuit of Cephalon, offering $5.7 billion for the business and threatening to walk in a

Sanofi raises big loan as it plots Genzyme buyout strategy

Sanofi-Aventis may not be able to get the time of day from Genzyme's board, but the pharma giant says its hostile takeover attempt faces no antitrust concerns in the U.S. Sanofi says that regulators

Sanofi insiders: Proxy fight could seal the Genzyme deal

With Genzyme's board dug in deep and unwilling to heed the siren call of an $18.5 billion buyout bid from Sanofi, some sources close to the European pharma company are telling Reuters that an

Sanofi turns hostile in Genzyme takeover attempt

Sanofi-Aventis has decided to turn its bear hug on Genzyme into a hostile embrace. In yet another slow but deliberate step, the pharma giant is taking its offer straight to shareholders, but so far

OSI shares soar as Astellas brawls over rejected bid

Astellas' hostile bid to acquire OSI Pharmaceuticals--along with its stake in the cancer blockbuster Tarceva and a pipeline of experimental therapies--is turning into a bruising brawl. Astellas filed

Astellas makes $3.5B hostile bid for OSI

Astellas Pharma announced today that it has made a $3.5 billion hostile bid to acquire OSI Pharmaceuticals, which is developing molecular targeted therapies for oncology, diabetes and obesity. The

Biogen ups the ante for Facet

Biogen Idec has made its "best-and-final offer" for Facet Biotech. The big biotech has upped its bid to $17.50 per share (around $430 million), up from the $14.50 per share--or $356 million--Biogen

Biogen turns hostile in $356M bid to acquire Facet

Biogen Idec (BIIB) won't take no as an answer to its buyout proposal for development partner Facet Biotech (FACT). Two weeks after Facet's board spurned Biogen's unsolicited offer of $14.50 a share,